Nexus Biomedical Devices Inc is categorized under Noncommercial Biotechnical Research in Santa Clara, CA and active since 2003.
Nexus Biomedical Devices Inc was established in 2003, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Noncommercial Biotechnical Research business, which does work in the B2B market, and is classified as a Noncommercial Biotechnical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Richard Fang at the company’s single location by writing to 473 Sapena Court # 7, Santa Clara, California CA 95054 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Nexus Biomedical Devices Inc |
| Contact Person: | Richard Fang |
| Address: | 473 Sapena Court # 7, Santa Clara, California 95054 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2003 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Noncommercial Biotechnical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Nexus Biomedical Devices Inc was started in 2003 to provide professional Noncommercial Biotechnical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Richard Fang for inquiries that concern Nexus Biomedical Devices Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Nexus Biomedical Devices Inc can be found at the coordinates as well as the street address 473 Sapena Court # 7 in Santa Clara, California 95054.
For its online presence, you may visit Nexus Biomedical Devices Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.